Lenalidomide Sandoz 25 Mg Hard Capsules

Lenalidomide, the active ingredient in Lenalidomide Sandoz 25 Mg Hard Capsules, is an immunomodulatory drug (IMiD) presented as a 25 mg hard capsule for oral use. It treats multiple myeloma, mantle cell lymphoma and myelodysplastic syndromes with del(5q) in adult patients.

GNH USA supplies Lenalidomide Sandoz 25 Mg Hard Capsules as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and specialized clinics worldwide.

Lenalidomide is an immunomodulatory agent used in hematologic malignancies and related disorders.

- Multiple Myeloma: improves progression‑free survival and overall response rates in patients with relapsed or refractory disease. - Mantle Cell Lymphoma: used in combination therapy to achieve tumor control in adult patients. - Myelodysplastic Syndromes with del(5q): reduces transfusion dependence and can lead to cytogenetic remission.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may require fluid replacement. - Nausea: mild to moderate stomach upset. - Rash: skin redness or itching.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: markedly reduced neutrophil count increasing infection risk. - Secondary primary malignancies: emergence of new cancers unrelated to the original disease.

Before prescribing Lenalidomide, clinicians should consider several safety and handling precautions.

- Pregnancy risk: contraindicated in pregnancy (Category X); effective contraception required. - Thrombosis risk: assess for prior clotting events and consider prophylactic anticoagulation. - Renal impairment: dose adjustment may be needed in patients with reduced kidney function. - Hepatic impairment: monitor liver enzymes and adjust therapy if necessary. - Infection monitoring: watch for signs of infection due to neutropenia. - Store at ambient temperature: keep below 25 °C, retain in original container, protect from moisture.

Lenalidomide can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers: may reduce lenalidomide exposure (e.g., rifampin). - Anticoagulants: increased risk of bleeding when combined with warfarin or DOACs.

Moderate Interactions (Monitor Closely): - Immunosuppressants: may enhance infection risk (e.g., cyclosporine). - Vaccines: live vaccines should be avoided during therapy. - NSAIDs: may increase risk of renal toxicity when used together.